Belite Bio Announces FDA Acceptance And Priority Review Of Tinlarebant NDA For Stargardt Disease Type 1, With PDUFA Date Of February 12, 2027

뉴스 본문을 불러오고 있어요.

Belite Bio Announces FDA Acceptance And Priority Review Of Tinlarebant NDA For Stargardt Disease Type 1, With PDUFA Date Of February 12, 2027 | 웨이프 WAPE

Belite Bio Announces FDA Acceptance And Priority Review Of Tinlarebant NDA For Stargardt Disease Type 1, With PDUFA Date Of February 12, 2027

기사 요약

관련 종목

댓글 —